Sanofi (SNYNF) Cost of Revenue (2009 - 2026)
Sanofi (SNYNF) posted Cost of Revenue of $3.7 billion for Q1 2026, down 75.81% sequentially from $15.2 billion in Q4 2025, and up 20.89% YoY from $3.0 billion in Q1 2025.
Sanofi (SNYNF) Cost of Revenue (2009 - 2026) Analysis & Trends
Sanofi (SNYNF) has 18 years of Cost of Revenue data on file, last reported at $3.7 billion in Q1 2026.
- Quarterly Cost of Revenue rose 20.89% year-over-year to $3.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.1 billion (up 35.71% YoY) and the FY2025 annual result came in at $15.2 billion, up 7.65% from the prior year.
- Cost of Revenue fell to $3.7 billion in Q1 2026 per SNYNF's latest filing, from $15.2 billion in the prior quarter.
- The five-year high for Cost of Revenue was $15.2 billion in Q4 2025, with the low at $3.0 billion in Q1 2025.
- Average Cost of Revenue over 5 years is $6.5 billion, with a median of $3.7 billion recorded in 2026.
- Year-over-year, Cost of Revenue surged 251.48% in 2022 and dropped 9.31% in 2024.
- Sanofi's Cost of Revenue stood at $14.0 billion in 2022, then declined by 2.76% to $13.6 billion in 2023, then increased by 3.86% to $14.1 billion in 2024, then gained by 7.65% to $15.2 billion in 2025, then plunged by 75.81% to $3.7 billion in 2026.
- Business Quant data shows SNYNF's Cost of Revenue at $3.7 billion in Q1 2026, $15.2 billion in Q4 2025, and $10.9 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 3.58 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 8.11 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 4.22 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 2.68 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 4.20 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.74 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 1.45 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 3.55 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Sanofi | - | - | 9.49 Bn | 3.67 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.67 Bn |
| Mar 31, 2026 | 3.67 Bn |
| Dec 31, 2025 | 15.19 Bn |
| Dec 31, 2025 | 15.19 Bn |
| Sep 30, 2025 | 10.86 Bn |
| Sep 30, 2025 | 10.86 Bn |
| Jun 30, 2025 | 3.39 Bn |
| Jun 30, 2025 | 3.39 Bn |
| Mar 31, 2025 | 3.04 Bn |
| Mar 31, 2025 | 3.04 Bn |
| Dec 31, 2024 | 14.11 Bn |
| Dec 31, 2024 | 14.11 Bn |
| Sep 30, 2024 | 4.02 Bn |
| Sep 30, 2024 | 4.02 Bn |
| Jun 30, 2024 | 3.23 Bn |
| Jun 30, 2024 | 3.23 Bn |
| Mar 31, 2024 | 3.23 Bn |
| Mar 31, 2024 | 3.23 Bn |
| Dec 31, 2023 | 13.59 Bn |
| Dec 31, 2023 | 13.59 Bn |